IOTA ADNEX at 10 Percent Has Higher Sensitivity for Ovarian Cancer
By Elana Gotkine HealthDay Reporter
.jpg?width=1200)
WEDNESDAY, Oct. 16, 2024 -- The International Ovarian Tumour Analysis consortium (IOTA) Assessment of Different Neoplasias in the Adnexa (ADNEX) at 10 percent is more sensitive, but less specific, for diagnosing ovarian cancer compared with Risk of Malignancy 1 (RMI1) at 250, according to a study published in the October issue of The Lancet Oncology.
Sudha Sundar, from the Institute of Cancer and Genomic Sciences at the University of Birmingham in the United Kingdom, and colleagues conducted a multicenter, prospective diagnostic accuracy study involving newly presenting female patients aged 16 to 90 years with nonspecific symptoms and elevated CA125, abnormal ultrasound results, or both. The analysis included only postmenopausal participants. Participants completed a symptom questionnaire, provided a blood sample, and underwent transabdominal and transvaginal ultrasounds. Data were included from 1,076 participants to examine diagnostic accuracy at predicting primary invasive ovarian cancer versus benign or normal histology.
The researchers found that compared with RMI1 at a threshold of 250 (sensitivity, 82.9 percent; specificity, 87.4 percent), IOTA ADNEX at 10 percent was more sensitive but less specific (difference of −13.9 and 28.5 percent, respectively). Similar sensitivity and lower specificity were seen with the Risk of Malignancy Algorithm at 29.9 (difference of −3.6 and 5.2 percent, respectively). Similar sensitivity and lower specificity were seen for RMI1 at 200 (difference of −2.1 and 3.0 percent, respectively) and for the IOTA Simple Rules Risk model at 10 percent (difference of −4.3 and 16.2 percent, respectively). IOTA Simple Rules had similar sensitivity and specificity (difference of −1.6 and −2.2 percent, respectively). CA125 at 35 IU/mL had similar sensitivity and higher specificity (difference of −2.1 and 6.7 percent, respectively).
"A health economic analysis is underway and will be crucial to understand the broader effects of our findings," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Urgent Care Visits Often Linked to Inappropriate Prescribing
MONDAY, July 21, 2025 -- Urgent care visits are often associated with inappropriate prescriptions of antibiotics, glucocorticoids, and opioids, according to a research letter...
Race Definitions Have Limited Impact on Cancer Rates in Whites, Blacks, Asians
MONDAY, July 21, 2025 -- Race definitions have limited impact on cancer rates for Whites, Blacks, and Asians, but do impact rates in multiracial individuals, according to a study...
Millions of Backyard Pools Recalled After Drowning Deaths of Nine Children
MONDAY, July 21, 2025 — Close to 5 million above-ground swimming pools have been recalled following the drowning deaths of nine children over two decades. The 48-inch and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.